EC
MXCT icon

EntryPoint Capital’s MaxCyte MXCT Stock Holding History

EntryPoint Capital’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-61,280
Closed -$134K – 801
2025
Q2 		$134K Sell
61,280
-67,939
-53% -$165K 0.07% 542
2025
Q1 		$353K Buy
129,219
+84,761
+191% +$334K 0.16% 245
2024
Q4 		$185K Buy
+44,458
New +$168K 0.08% 606
2024
Q2 		– Sell
-6,883
Closed -$28.8K – 1364
2024
Q1 		$28.8K Sell
6,883
-23,971
-78% -$113K 0.03% 970
2023
Q4 		$145K Buy
+30,854
New +$120K 0.14% 205

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's MXCT Position: Q3 2025 in Review

EntryPoint Capital sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 61,280 shares — an estimated $134K sold.

EntryPoint Capital first reported a position in MXCT in Q4 2023 and held it in 5 quarters. The position peaked at $353K in Q1 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • EntryPoint Capital reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • EntryPoint Capital sold 61,280 MaxCyte shares in Q3 2025, an estimated $134K.
  • EntryPoint Capital first reported a position in MaxCyte in Q4 2023 and held it in 5 quarters.
  • EntryPoint Capital's MaxCyte position peaked at $353K in Q1 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.